In favour of a bespoke COVID-19 vaccines compensation scheme.
In favour of a bespoke COVID-19 vaccines compensation scheme.
复制标题
DOI：
10.1016/s1473-3099(21)00065-7
复制
发表时间：
2021-04
期刊：
影响因子：
--
通讯作者：
Vanderslott S
中科院分区：
文献类型：
--
作者：
Fairgrieve D;Holm S;Howells G;Kirchhelle C;Vanderslott S
三种疫苗在英国获得许可，以及来自更多候选疫苗的初步数据，使我们有理由希望2021年新冠肺炎的发病率大幅降低。疫苗的普及将取决于确保充足的疫苗供应，建立强有力和公平的分配方案，并通过充分的法律保障措施加强公众对疫苗安全性的信任，以防止和补偿无意中的伤害。调查和社会学研究表明，在过去十年中，一些国家对疫苗的犹豫不决的情况令人担忧。1因此，至关重要的是投入足够的资源，创造最大限度地吸收和最大限度减少犹豫不决的机会的条件。现在是时候这么做了。领先的新冠肺炎候选疫苗所基于的新技术和错误的信息宣传活动已经增加了公众的不确定性。现在已经开始推出了，
The licensing of three vaccines in the UK and preliminary data from further vaccine candidates give reason to hope for substantial reductions of COVID-19 incidence in 2021. Uptake will depend on securing sufficient vaccine supplies, creating a robust and equitable distribution scheme, and fostering public trust in the safety of the vaccines with adequate legal safeguards to prevent and compensate for inadvertent harm.Surveys and sociological research indicate a worrying increase in vaccine hesitancy in some countries over the past decade. 1 It is, therefore, vital to invest sufficient resources in creating conditions that maximise uptake and minimise opportunities for hesitancy. The time to do so is now. The novel technologies on which leading COVID-19 vaccine candidates are based and misinformation campaigns are already contributing to public uncertainty. Now that roll-outs have started,